The TASC Trial: Therapeutic vs Prophylactic Anticoagulation for Acute Chest Syndrome
In adults with sickle cell disease hospitalized for acute chest syndrome (ACS) without pulmonary artery macrothrombosis, does therapeutic-dose anticoagulation with tinzaparin shorten ACS duration compared with prophylactic-dose anticoagulation?
